<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">BMC Psychiatry</journal-id><journal-title-group><journal-title>BMC Psychiatry</journal-title></journal-title-group><issn pub-type="epub">1471-244X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27048333</article-id><article-id pub-id-type="pmc">4822232</article-id><article-id pub-id-type="publisher-id">794</article-id><article-id pub-id-type="doi">10.1186/s12888-016-0794-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>The effect of oxytocin on attention to angry and happy faces in chronic depression</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Domes</surname><given-names>Gregor</given-names></name><address><phone>+49 761 2033035</phone><email>domes@psychologie.uni-freiburg.de</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Normann</surname><given-names>Claus</given-names></name><address><email>claus.normann@uniklinik-freiburg.de</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Heinrichs</surname><given-names>Markus</given-names></name><address><email>heinrichs@psychologie.uni-freiburg.de</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><aff id="Aff1"><label/>Department of Psychology, Laboratory for Biological and Personality Psychology, University of Freiburg, Stefan-Meier-Strasse 8, D-79104 Freiburg, Germany </aff><aff id="Aff2"><label/>Freiburg Brain Imaging, University Medical Center Freiburg, Freiburg, Germany </aff><aff id="Aff3"><label/>Department of Psychiatry and Psychotherapy, University Medical Center Freiburg, Freiburg, Germany </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>4</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>6</day><month>4</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>16</volume><elocation-id>92</elocation-id><history><date date-type="received"><day>25</day><month>7</month><year>2015</year></date><date date-type="accepted"><day>31</day><month>3</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; Domes et al. 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Chronic depression is characterized by a high degree of early life trauma, psychosocial impairment, and deficits in social cognition. Undisturbed recognition and processing of facial emotions are basic prerequisites for smooth social interactions. Intranasal application of the neuropeptide oxytocin has been reported to enhance emotion recognition in neuropsychiatric disorders and healthy individuals. We therefore investigated whether oxytocin modulates attention to emotional faces in patients with chronic depression.</p></sec><sec><title>Methods</title><p>In this double-blind, randomized, controlled study, 43 patients received a single dose of oxytocin or placebo nasal spray and were tested while fulfilling a facial dot probe task. We assessed reaction times to neutral probes presented at the location of one of two faces depicting happy, angry, or neutral expressions as a prime.</p></sec><sec><title>Results</title><p>When comparing reaction times to the congruent (prime and probe at the same location) with incongruent presentation of facial emotions, neither the placebo nor oxytocin group showed an attentional preference for emotional facial expressions in terms of a threat bias. However, oxytocin treatment did reveal two specific effects: it generally reduced the allocation of attention towards angry facial expressions, and it increased sustained attention towards happy faces, specifically under conditions of heightened awareness, i.e. trials with longer primes.</p></sec><sec><title>Conclusions</title><p>We investigated a heterogeneous group of medicated male and female patients. We conclude that oxytocin does modulate basic factors of facial emotion processing in chronic depression. Our findings encourage further investigations assessing the therapeutic potential of oxytocin in chronic depression.</p></sec><sec><title>Trial registration</title><p><ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020956-69">EUDRA-CT 2010-020956-69</ext-link>. Date registered: 23 February 2011.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Oxytocin</kwd><kwd>Chronic depression</kwd><kwd>Facial emotions</kwd><kwd>Attention</kwd><kwd>Dot probe</kwd><kwd>Social perception</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft (DE)</institution></institution-wrap></funding-source><award-id>Do1312/2-1</award-id><principal-award-recipient><name><surname>Domes</surname><given-names>Gregor</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft (DE)</institution></institution-wrap></funding-source><award-id>Do1312/2-3</award-id><principal-award-recipient><name><surname>Domes</surname><given-names>Gregor</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft (DE)</institution></institution-wrap></funding-source><award-id>He5310/1-1</award-id><principal-award-recipient><name><surname>Heinrichs</surname><given-names>Markus</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>In about a third of patients with major depressive disorder, the depression becomes chronic, defined as the illness lasting longer than two years [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. However, chronic depression is not just the prolonged course of a major depressive disorder - it differs in several key psychopathological aspects from the episodic course of depression. Chronically depressed patients are characterized by a high degree of early life trauma, specifically emotional abuse and neglect [<xref ref-type="bibr" rid="CR3">3</xref>]; they report more negative interpersonal experiences with significant others than patients with episodic depression [<xref ref-type="bibr" rid="CR4">4</xref>] and experience worse impaired psychosocial function [<xref ref-type="bibr" rid="CR1">1</xref>]. These features, and clinical experience from the psychological treatment of chronically depressed patients, have led to the hypothesis that patients with chronic depression are arrested in the &#x0201c;preoperational developmental stage&#x0201d; according to Piaget, which is characterized by an egocentric perspective on the world and impaired interpersonal empathy and theory of mind [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>].</p><sec id="Sec2"><title>Facial emotion recognition and attentional bias in depression</title><p>Facial emotion recognition contributes to the cognitive facet of empathy and represents a basic requisite to understanding social interactions. Numerous studies have assessed facial emotion recognition in major depression (for a review: [<xref ref-type="bibr" rid="CR8">8</xref>]). Although the accuracy of facial emotion recognition seems to be normal, there is considerable evidence of a negative response bias towards sadness and increased vigilance and selective attention to negative emotions in depressed individuals [<xref ref-type="bibr" rid="CR9">9</xref>]. Facial emotion recognition and attentional bias towards negative facial cues have not been assessed specifically in chronic depression. Given the high degree of psychosocial impairment that chronically depressed patients suffer, better understanding of the attentional processes for social signals in chronic depression and their neurobiological modulation might be especially relevant for clinical treatment.</p></sec><sec id="Sec3"><title>The role of attention in face processing</title><p>Socially-relevant stimuli such as emotional facial expressions normally capture our attention. Enhanced attention to emotional faces can be inferred from studies showing that emotional faces are more easily detected than neutral stimuli, as evident in visual search paradigms [<xref ref-type="bibr" rid="CR10">10</xref>] and rapid serial presentation paradigms [<xref ref-type="bibr" rid="CR11">11</xref>]. Thus, increased attentional preference for a given stimulus category indicates the greater motivational relevance or saliency of this specific stimulus.</p><p>A widely-used paradigm to assess attentional preference for a given category of emotional stimuli is the dot probe task [<xref ref-type="bibr" rid="CR12">12</xref>]. In short, in the classical dot probe task, two stimuli (e.g. an emotional and neutral face) are presented simultaneously on a screen, followed by a probe, which is presented either at the target&#x02019;s location (congruent) or at the distractor&#x02019;s location (incongruent). Attentional preference for the target is inferred from the so-called congruency effect, i.e. if the reaction times (RTs) are significantly faster in congruent than incongruent trials.</p><p>Although several studies have confirmed a robust, threat-related bias in terms of an enhanced congruency effect in response to highly aversive/threatening stimuli in anxious populations, the congruency effect has been revealed as less consistent in healthy or subclinical samples [<xref ref-type="bibr" rid="CR13">13</xref>]. It should be noted that most studies used verbal material or complex, emotionally-laden visual scenes as target stimuli in the dot probe task.</p><p>There is considerable evidence that depressed patients demonstrate an attentional bias towards negative information including social cues such as negative facial expressions (for a review: [<xref ref-type="bibr" rid="CR9">9</xref>]). Initial evidence of biased attention towards emotional facial expressions arises from studies involving subclinical dysphoric samples. Dysphoric people demonstrate the tendency to avoid happy facial expressions [<xref ref-type="bibr" rid="CR14">14</xref>], and low dysphoria is associated with an attentional bias away from angry faces [<xref ref-type="bibr" rid="CR15">15</xref>]. There is a paucity of studies investigating patients diagnosed with major depression. Initial evidence exists of an attentional bias towards sad faces [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], and angry faces [<xref ref-type="bibr" rid="CR18">18</xref>], although other investigators did not detect biased attention to either facial stimuli in depression [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p>Some researchers have argued in favor of at least two processes underlying the congruency effect: the effect of initial allocation of attention to the salient prime in congruent trials, and the inability to reallocate attention to the probe&#x02019;s location in incongruent trials. While the former might be largely due to vigilance, the latter can be referred to as adherence, or the difficulty of disengaging from the prime. Indeed, previous studies found that the congruency effect in the dot-probe task was largely due to enhanced adherence to the threat stimulus rather than increased vigilance [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. It might therefore be particularly interesting to explicitly differentiate between treatment effects on the initial allocation of attention towards a specific stimulus category and attentional adherence to the stimulus.</p></sec><sec id="Sec4"><title>Oxytocin, face processing, and social attention</title><p>The nine-amino-acid oxytocin is known to modulate social interaction in animals and humans [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Experimental studies in humans have associated oxytocin with an enhanced ability to recognize facial emotions [<xref ref-type="bibr" rid="CR24">24</xref>] in both healthy individuals [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>] and in those with impaired facial emotion recognition abilities such as autism [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] or schizophrenia [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. There is recent evidence that oxytocin increases covert attention to positive facial cues in healthy males [<xref ref-type="bibr" rid="CR33">33</xref>]. Another study using a spatial cueing paradigm reported facilitated attentional disengagement from negative facial expression stimuli after the intranasal administration of oxytocin [<xref ref-type="bibr" rid="CR34">34</xref>]. Moreover, there is evidence of positive effects on overt visual attention to the eye region in both neutral and emotional faces [<xref ref-type="bibr" rid="CR35">35</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref>], suggesting that attention modulation might be a significant mediator in the beneficial effects of oxytocin on emotion recognition, although this link must still be demonstrated [<xref ref-type="bibr" rid="CR27">27</xref>]. Finally, there are initial findings that oxytocin also has beneficial effects on affective symptoms and social cognitive functioning in patients with episodic depression [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>].</p></sec><sec id="Sec5"><title>Aims and hypotheses</title><p>The present study aimed to investigate whether a single dose of intranasally applied oxytocin would modulate attention towards social signals of threat (angry faces) and social approach (happy faces) in a group of patients with chronic depression. Angry faces were chosen on the basis of previous studies addressing the attention effects of oxytocin in a social context [<xref ref-type="bibr" rid="CR33">33</xref>&#x02013;<xref ref-type="bibr" rid="CR35">35</xref>] and previous findings demonstrating a bias towards angry faces in depressed patients [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. Ellenbogen et al. demonstrated that oxytocin attenuated the attentional bias to masked angry faces in persons with high depression scores [<xref ref-type="bibr" rid="CR34">34</xref>]. Based on findings of reduced attention to positive facial cues in depression and oxytocin&#x02019;s effects on attention summarized above, we specifically hypothesized that patients receiving oxytocin prior to a facial dot probe task would reveal greater attention towards happy faces than placebo controls, as indicated by a greater congruency effect. Furthermore, we were interested in determining whether oxytocin treatment would affect initial attention allocation or adherence to the emotional target.</p></sec></sec><sec id="Sec6"><title>Methods</title><sec id="Sec7"><title>Participants</title><p>Forty-three patients with chronic depression were recruited from the in-patient and out-patient units of the Department of Psychiatry and Psychotherapy at the University Medical Center Freiburg. Patients were considered for the study if they met the criteria for chronic depression as defined by depressive symptomatology for more than two years in the course of a depressive episode or a recurrent depressive disorder (ICD-10: F32.1, F32.2, F33.1, F33.2). In addition, many patients fulfilled the criteria for dysthymia (ICD-10: F34.0) and therefore suffered from double depression (depressive episode&#x02009;+&#x02009;dysthymia). Patients were excluded from the study if they met any of the following criteria: bipolar disorder, current psychotic symptoms, alcohol or drug addiction, a clinical autism diagnosis, severe uncorrected visual impairment. Of the total sample, 41 were taking psychoactive medication: 9 patients were taking SSRI, 15 SSNRI, 7 tri-/tetracyclic antidepressants, 6 DNRI, and 4 were taking a neuroleptic or others. Patients were randomly allocated to receive a single dose of intranasally administered oxytocin (<italic>n</italic>&#x02009;=&#x02009;22) or a placebo (<italic>n</italic>&#x02009;=&#x02009;21) before the dot-probe task under double-blind conditions. For demographic and clinical characteristics of these groups, see Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. The study protocol was approved by the ethics committee of the University of Freiburg. Patients provided written-informed consent once the study procedures had been fully explained.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Demographic and clinical characteristics of the study groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2"/><th colspan="2">Placebo (<italic>n</italic>&#x02009;=&#x02009;21)</th><th colspan="2">Oxytocin (<italic>n</italic>&#x02009;=&#x02009;22)</th></tr><tr><th colspan="2"/><th>m</th><th>(s.d.)</th><th>m</th><th>(s.d.)</th></tr></thead><tbody><tr><td colspan="2">Age</td><td>47.2</td><td>(9.0)</td><td>46.7</td><td>(11.1)</td></tr><tr><td colspan="2">Sex (m/f)</td><td>9/12</td><td/><td>9/13</td><td/></tr><tr><td colspan="2">Years in school</td><td>11.3</td><td>(2.0)</td><td>11.0</td><td>(1.5)</td></tr><tr><td colspan="2">IQ (WST)</td><td>106.6</td><td>(9.7)</td><td>108.7</td><td>(9.6)</td></tr><tr><td colspan="2">Depression (BDI)</td><td>28.0</td><td>(9.5)</td><td>29.1</td><td>(11.9)</td></tr><tr><td colspan="2">Trait anxiety (STAI)</td><td>60.9</td><td>(8.3)</td><td>61.4</td><td>(8.1)</td></tr><tr><td colspan="2">Medication (y/n)</td><td>19/2</td><td/><td>22/0</td><td/></tr><tr><td colspan="2">Illness duration (years)</td><td>12.9</td><td>(10.2)</td><td>14.8</td><td>(12.1)</td></tr><tr><td>Calmness</td><td>pre</td><td>13.0</td><td>(3.2)</td><td>12.5</td><td>(2.5)</td></tr><tr><td/><td>post</td><td>11.8</td><td>(2.9)</td><td>11.6</td><td>(2.4)</td></tr><tr><td>Wakefulness</td><td>pre</td><td>13.1</td><td>(3.5)</td><td>12.8</td><td>(4.2)</td></tr><tr><td/><td>post</td><td>10.3</td><td>(3.6)</td><td>11.0</td><td>(3.4)</td></tr><tr><td>Mood</td><td>pre</td><td>12.9</td><td>(3.2)</td><td>12.5</td><td>(2.5)</td></tr><tr><td/><td>post</td><td>11.8</td><td>(2.9)</td><td>11.6</td><td>(2.4)</td></tr></tbody></table><table-wrap-foot><p>WST, Wortschatztest; BDI, Beck Depression Inventory; STAI, State-Trait Anxiety Inventory</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec8"><title>Psychometric assessment</title><p>All patients completed the Beck Depression Inventory [<xref ref-type="bibr" rid="CR41">41</xref>], the State-Trait-Anxiety Questionnaire [<xref ref-type="bibr" rid="CR42">42</xref>] and multi-dimensional mood questionnaire [<xref ref-type="bibr" rid="CR43">43</xref>] to assess trait depression, anxiety and changes in calmness, wakefulness and mood over the course of the experiment. The short version of the multidimensional mood questionnaire employed here comprises 12 items on three scales, measuring state calmness, wakefulness, and mood using 5-point Likert scales. The questionnaire has proven good reliability and validity and is a sensitive measure to capture state-dependent changes in calmness, wakefulness and mood [<xref ref-type="bibr" rid="CR43">43</xref>].</p></sec><sec id="Sec9"><title>Experimental procedures</title><p>After completing demographic, clinical and mood-state questionnaires, patients self-administered 6 puffs of Syntocinon&#x000ae; nasal spray (Novartis, Basel, Switzerland; 3 puffs per nostril, containing 4&#x000a0;IU oxytocin each) or a placebo under the supervision of the experimenter. After approx. 45&#x000a0;min, participants completed a basic facial emotion recognition experiment before being asked to complete a dot-probe task to assess attentional preference for facial stimuli with varying valence [<xref ref-type="bibr" rid="CR12">12</xref>]. The dot-probe thus started approx. 60&#x000a0;min after intranasal oxytocin administration.</p><p>As prime stimuli, happy, angry and neutral facial expressions of 40 persons (20 male/20 female) were selected from the Karolinska Directed Emotional Faces database [<xref ref-type="bibr" rid="CR44">44</xref>]. An overview of trial structure and experimental conditions is provided in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. A trial started with a blank screen for 1000&#x000a0;ms followed by a fixation cross for 750 to 1500&#x000a0;ms. Then a pair of angry/neutral, happy/neutral or neutral/neutral faces of the same person was presented (each 295&#x02009;&#x000d7;&#x02009;400&#x000a0;pixels, 12.2&#x02009;&#x000d7;&#x02009;16.5&#x000b0; visual angle) with an vertical offset of +/&#x02212; 200&#x000a0;pixels (8.3&#x000b0; visual angle) from the screen center lasting 100, 600, or 1200&#x000a0;ms. Immediately following the presentation of faces, a dot probe was presented at the location of one of the faces. For the angry/neutral and happy/neutral pairs, the probe (a small black box, 10&#x02009;&#x000d7;&#x02009;10&#x000a0;pixels) appeared in the center of the emotional face (congruent) or the neutral face (incongruent) in half of the trials. Participants were asked to press as quickly as possible either of two buttons located in front of them on a table to indicate the probe&#x02019;s location. The numbers of correct responses and RTs to the dot probes were recorded. At each presentation time (100, 600, 1200&#x000a0;ms), 120 trials were presented comprising 40 trials for each pairing of faces (angry-neutral, happy-neutral, neutral-neutral). In all, there were 360 trials lasting a maximum approx. 30&#x000a0;min. The experiment was run on a Windows PC with a 22&#x0201d; TFT display (40.8&#x02009;&#x000d7;&#x02009;30.6&#x000a0;cm; 1650&#x02009;&#x000d7;&#x02009;1050&#x000a0;pixel) using Presentation (Version 12.1, Neurobehavioral Systems, Albany CA, USA). Viewing distance was kept constant at 65&#x000a0;cm using a chin-/headrest.<fig id="Fig1"><label>Fig. 1</label><caption><p>Trial structure and experimental conditions of the dot probe task. Following a fixation cross for 750&#x02013;1500&#x000a0;ms, primes were presented simultaneously for either 100, 600, or 1200&#x000a0;ms. RTs were measured from the onset of the dot probe which followed the primes until the button press</p></caption><graphic xlink:href="12888_2016_794_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec10"><title>Statistical analyses</title><p>Raw RTs in erroneous trials with erroneous responses, and RTs below 300&#x000a0;ms and above 1500&#x000a0;ms were excluded from further analysis. In all, 15,480 trials were presented to the 43 participants in the study. Of these, 480 (3.1&#x000a0;%) were discarded from the analysis, 145 (0.9&#x000a0;%) were out of the time range and 335 (2.2&#x000a0;%) were errors. RT outliers and errors did not differ between the experimental conditions (all <italic>p</italic>&#x02009;&#x0003c;&#x02009;.10).</p><p>Raw RTs were analyzed via a four-way ANOVA comprising the factors group (oxytocin, placebo), prime duration (100, 600, 1000&#x000a0;ms), prime valence (happy, angry), and condition (congruent, incongruent).</p><p>Attentional bias for specific emotional facial expressions was calculated by subtracting averaged RTs to congruent trials from averaged RTs to incongruent trials within each condition (congruency effect). These bias scores were subject to a three-way ANOVA with group (oxytocin, placebo) as the between-subject factor, and presentation duration (100, 600, 1200&#x000a0;ms) and prime valence (angry, happy) as within-subject factors.</p><p>We also calculated prime-valence effects on initial allocation and adherence by contrasting RTs on congruent and incongruent trials with RTs on neutral control trials. Faster RT to congruent than to neutral trials reveals initial allocation of attention to the position of the salient prime location and result in positive values for the contrast &#x00394;RT<sub>allocation</sub>&#x02009;=&#x02009;RT<sub>neutral</sub> &#x02013; RT<sub>congruent</sub>. In turn, responding slower to incongruent than to neutral trials indicates adherence to the position of the salient prime and result in positive values for the contrast &#x00394;RT<sub>adherence</sub>&#x02009;=&#x02009;RT<sub>incongruent</sub> &#x02013; RT<sub>neutral</sub>. Again, both allocation and adherence scores were subjected to separate three-way ANOVAs with the factors group, presentation duration, and prime valence. Post-hoc testing employed separate follow-up two-way ANOVAs for happy and angry primes with the factors group (oxytocin, placebo) and prime duration (100, 600, 1200&#x000a0;ms).</p><p>Statistical significance was set to <italic>p</italic>&#x02009;&#x0003c;&#x02009;.05. In case of non-homogenous variances, the Greenhouse-Geisser correction was employed. All statistical analyses were done with SPSS 20 for Windows.</p></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>Demographic and clinical characteristics of the study group</title><p>The two study groups were equivalent regarding age, education, gender distribution, IQ, trait anxiety, and depression. Although we noted a significant reduction in calmness, wakefulness, and mood over the course of the experiment (all <italic>p</italic>&#x02009;&#x0003c;&#x02009;.05), this effect did not substantially differ between the oxytocin and placebo group (all <italic>p</italic>&#x02009;&#x0003e;&#x02009;.10). Descriptive data are given in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.</p></sec><sec id="Sec13"><title>Raw reaction time data</title><p>In the first step, we analyzed differences in raw RT data for the factors drug condition, congruency, prime duration, and emotional valence of prime. The four-way ANOVA revealed a significant main effect of prime duration, indicating overall shorter RTs on primes with longer duration (F[2,82]&#x02009;=&#x02009;16.83; <italic>p</italic>&#x02009;&#x0003c;&#x02009;.001; &#x003b7;<sup>2</sup><sub>part</sub>&#x02009;=&#x02009;.291). No other effect attained significance, indicating that RTs were neither modulated by the emotional valence of the prime nor by the probe&#x02019;s location. Furthermore, we observed no drug-condition effect (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Average raw RTs in milliseconds (s.d.) for the experimental conditions in the dot-probe task</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">Placebo (<italic>n</italic>&#x02009;=&#x02009;21)</th><th colspan="2">Oxytocin (<italic>n</italic>&#x02009;=&#x02009;22)</th></tr><tr><th/><th>Congruent</th><th>Incongruent</th><th>Congruent</th><th>Incongruent</th></tr></thead><tbody><tr><td>Happy</td><td/><td/><td/><td/></tr><tr><td>&#x02003;100&#x000a0;ms</td><td>608 (96)</td><td>600 (94)</td><td>612 (99)</td><td>590 (83)</td></tr><tr><td>&#x02003;600&#x000a0;ms</td><td>578 (95)</td><td>575 (95)</td><td>579 (93)</td><td>572 (95)</td></tr><tr><td>&#x02003;1200&#x000a0;ms</td><td>551 (93)</td><td>554 (81)</td><td>577 (95)</td><td>578 (90)</td></tr><tr><td>Angry</td><td/><td/><td/><td/></tr><tr><td>&#x02003;100&#x000a0;ms</td><td>598 (117)</td><td>585 (107)</td><td>602 (82)</td><td>609 (100)</td></tr><tr><td>&#x02003;600&#x000a0;ms</td><td>568 (89)</td><td>562 (102)</td><td>580 (83)</td><td>579 (85)</td></tr><tr><td>&#x02003;1200&#x000a0;ms</td><td>550 (93)</td><td>555 (92)</td><td>581 (97)</td><td>568 (91)</td></tr><tr><td>Neutral</td><td/><td/><td/><td/></tr><tr><td>&#x02003;100&#x000a0;ms</td><td colspan="2">586 (92)</td><td colspan="2">599 (86)</td></tr><tr><td>&#x02003;600&#x000a0;ms</td><td colspan="2">565 (85)</td><td colspan="2">570 (80)</td></tr><tr><td>&#x02003;1200&#x000a0;ms</td><td colspan="2">555 (85)</td><td colspan="2">559 (83)</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec14"><title>Attentional bias &#x02013; congruency effect</title><p>To analyze the modulation of attentional preference for happy vs. angry faces at different prime durations, we analyzed attentional bias scores (difference between RTs to congruent vs. incongruent trials). In the three-way ANOVA testing for effects of prime duration, prime valence and drug condition, neither any of the main effects nor any of the interactions attained significance. We thus detected no overall modulation of attentional preference for emotional facial expressions in terms of a congruency effect (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Attentional bias scores (in ms) for the different experimental conditions in the dot-probe task</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">Placebo (<italic>n</italic>&#x02009;=&#x02009;21)</th><th colspan="2">Oxytocin (<italic>n</italic>&#x02009;=&#x02009;22)</th></tr><tr><th/><th>m</th><th>(s.d.)</th><th>m</th><th>(s.d.)</th></tr></thead><tbody><tr><td>Happy</td><td/><td/><td/><td/></tr><tr><td>&#x02003;100&#x000a0;ms</td><td>&#x02212;7.7</td><td>(38.8)</td><td>&#x02212;21.4</td><td>(55.5)</td></tr><tr><td>&#x02003;600&#x000a0;ms</td><td>&#x02212;2.7</td><td>(46.8)</td><td>&#x02212;7.9</td><td>(43.8)</td></tr><tr><td>&#x02003;1200&#x000a0;ms</td><td>3.0</td><td>(47.4)</td><td>0.9</td><td>(35.5)</td></tr><tr><td>Angry</td><td/><td/><td/><td/></tr><tr><td>&#x02003;100&#x000a0;ms</td><td>&#x02212;13.3</td><td>(44.3)</td><td>8.3</td><td>(39.7)</td></tr><tr><td>&#x02003;600&#x000a0;ms</td><td>&#x02212;6.2</td><td>(41.9)</td><td>&#x02212;0.6</td><td>(38.6)</td></tr><tr><td>&#x02003;1200&#x000a0;ms</td><td>4.0</td><td>(40.7)</td><td>&#x02212;11.6</td><td>(52.7)</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec15"><title>Allocation vs. adherence</title><p>To further investigate effects on the initial allocation of attention towards the salient emotional prime and effects on adherence on salient primes, we performed two separate three-way ANOVAs. In the allocation scores, we noted significant interaction between prime duration and drug condition (F[2,82]&#x02009;=&#x02009;3.54; <italic>p</italic>&#x02009;=&#x02009;.033; &#x003b7;<sup>2</sup><sub>part</sub>&#x02009;=&#x02009;.080): For both happy and angry faces, the placebo group displayed a greater initial allocation of attention with increasing duration of the salient emotional prime, while the oxytocin group demonstrated decreased initial allocation towards the emotional prime with increasing prime duration (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref>). In the follow-up two-way ANOVA with the factors group and prime duration for angry primes, we noted a significant group by prime duration interaction (F[2,82]&#x02009;=&#x02009;3.20; <italic>p</italic>&#x02009;=&#x02009;.046, &#x003b7;<sup>2</sup><sub>part</sub>&#x02009;=&#x02009;.073), while there was no such effect in the follow-up ANOVA for happy faces (F[2,82]&#x02009;=&#x02009;1.87; <italic>p</italic>&#x02009;=&#x02009;.161), suggesting reduced allocation of attention with increasing duration of the angry prime after oxytocin treatment.<fig id="Fig2"><label>Fig. 2</label><caption><p>Effects of oxytocin on the initial allocation of attention to the emotional prime and adherence on the emotional prime face as a function of presentation duration and emotional valence. <bold>a</bold> Allocation scores are calculated by subtracting the average RT to congruent trials from the average RT to neutral trials. Thus, negative values represent longer RTs to probes at the congruent location of the emotional face compared to neutral trials. <bold>b</bold> Adherence scores are calculated by subtracting the average RT to neutral trials from the average RT to incongruent trials. Thus, positive scores indicate sustained attention to the emotional prime</p></caption><graphic xlink:href="12888_2016_794_Fig2_HTML" id="MO2"/></fig></p><p>For adherence scores, i.e. slower attentional disengagement from the salient prime, we identified a significant interaction between prime valence and drug condition (F[2,82]&#x02009;=&#x02009;6.64; <italic>p</italic>&#x02009;=&#x02009;.014; &#x003b7;<sup>2</sup><sub>part</sub>&#x02009;=&#x02009;.139) and a marginally significant interaction of prime valence, prime duration and drug condition (F[2,82]&#x02009;=&#x02009;2.57; <italic>p</italic>&#x02009;=&#x02009;.083; &#x003b7;<sup>2</sup><sub>part</sub>&#x02009;=&#x02009;.059). While the oxytocin group demonstrated greater adherence to happy faces with increasing prime duration than the placebo group, there was no such modulation for angry faces (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2b</xref>). Follow-up two-way ANOVAs with the factors group and prime duration confirmed the differential effect of oxytocin with happy and angry faces: for happy faces a significant prime duration by drug interaction was observed, (F[2,82]&#x02009;=&#x02009;3.21; <italic>p</italic>&#x02009;=&#x02009;.046; &#x003b7;<sup>2</sup><sub>part</sub>&#x02009;=&#x02009;.073), while there was no significant effect in association with the angry faces (F[2,82]&#x02009;=&#x02009;0.08; <italic>p</italic>&#x02009;=&#x02009;.992).</p></sec></sec><sec id="Sec16"><title>Discussion</title><p>This study provides initial evidence for an oxytocin-induced modulation of attention towards positive and negative social signals in chronic depression. Although no congruency effect was observed in the present study, and the placebo group demonstrated no negativity or threat-bias, oxytocin did reduce the initial allocation of attention towards angry faces, and it increased sustained attention towards happy faces, specifically under conditions of heightened awareness, i.e. during trials with longer prime duration.</p><p>The lack of an overall attentional threat bias concurs with some previous studies and might be attributable to this measure&#x02019;s limited sensitivity, especially when attention allocation and adherence reveal reversed effects and thus cancel each other out [<xref ref-type="bibr" rid="CR21">21</xref>]. Inspecting the pattern of results (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>), this might be the case in the present study, since oxytocin exhibits opposing effects in conjunction with allocation and adherence of attention depending on the emotion presented.</p><p>Increased adherence or an attenuated tendency to disengage from the incongruent salient prime seems to be the primary factor underlying the congruency effect in investigations with anxious patients [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Although there are very few studies addressing visual attention to specific social cues in depression and (to our knowledge) none examining chronic depression, there is initial evidence that patients suffering from major depression display reduced attention to positive social cues (happy faces) and increased attention to negative (sad and angry) ones [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. In this study, we report increased adherence to positive social cues after oxytocin treatment, a finding in line with an earlier study using eye-tracking in healthy participants [<xref ref-type="bibr" rid="CR35">35</xref>]. This effect might in part compensate for the attentional negativity bias previously observed, and might thus demonstrate beneficial effects on social interaction in chronic depression.</p><p>Furthermore, our data suggest decreased initial allocation for negative facial expressions in the group receiving oxytocin compared to placebo. Notably, a recent study demonstrated that selective attention toward angry faces is a significant predictor for the recurrence of depression [<xref ref-type="bibr" rid="CR40">40</xref>]. In light of these results, an oxytocin-induced shift of attention from negative to positive social cues might exert protective effects in the course of chronic illness or recurrent depression. However, the oxytocin group&#x02019;s negative allocation-score values regarding increased prime durations indicate prolonged reaction times to congruent probes, although the attentional focus is presumably primed to the correct location. One plausible explanation for this paradoxical priming effect is the possibility that processing the facial stimulus interferes with the response to the probe. Negative allocation scores might therefore also indicate increased adherence to the salient congruent prime, and could reveal increased attention to the prime faces rather than a reduced allocation of attention.</p><p>The following limitations should be acknowledged. Although we observed significant modulations in attentional processes via the experimental intranasal administration of a single dose of oxytocin in a group of patients with chronic depression, interpretations regarding its clinical application should be made cautiously. First, the overall effects observed in this study were small and thus require replication. Attention to social stimuli is obviously just one of many other factors contributing to real-life social interactions. Follow-up studies are thus needed to evaluate the relative contribution of attentional processes to social functioning. Second, we investigated a heterogeneous group of male and female patients of whom almost all were taking psychoactive medication. It would therefore be an interesting topic for future studies to elucidate the role of sex and gonadal steroids in the effects we observed, as well as any interactions with serotonergic or noradrenergic medication. Third, long-term randomized controlled clinical trials are needed to evaluate the usefulness of intranasal oxytocin as an add-on to well-established cognitive behavioral treatment programs or pharmacotherapy in chronic depression. Previous studies suggest altered facial emotion perception related to personality disorders [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. In the present study none of the patients had a clinical diagnosis of BPD or any other personality disorder. However, lacking a structured interview, we cannot rule out that some patients met some of those criteria.</p></sec><sec id="Sec17"><title>Conclusions</title><p>To summarize: there is increasing evidence of a role played by oxytocin in human social cognition and interaction [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. In addition, recent studies suggest that individuals with impaired social cognitive abilities might benefit from increased availability of central nervous oxytocin [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR48">48</xref>&#x02013;<xref ref-type="bibr" rid="CR52">52</xref>]. Previous studies with depressed patients have reported positive effects of oxytocin on affective symptoms and social cognition [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Here we report increased attention to emotional faces in chronic depression using an experimental paradigm specifically tailored to disentangle the effects on allocation and adherence of visual attention for positive and negative social cues. In particular, our results suggest decreased allocation of attention to aversive social signals, and increased adherence to positive social signals after oxytocin treatment in patients with chronic depression. Given the psychopathological differences between episodic and chronic depression, the present study might be considered a point of departure for deeper research into the role of oxytocin in chronic depression &#x02013; a disorder characterized by pronounced and disabling difficulties in social cognition and functioning [<xref ref-type="bibr" rid="CR1">1</xref>].</p><sec id="Sec18"><title>Ethical approval and consent to participate</title><p>The ethics committee at the University of Freiburg approved the study (EK.-Nr. 307/10) and participants gave written-informed consent before participation.</p></sec><sec id="Sec19"><title>Consent to publish</title><p>Consent to publish is not required.</p></sec><sec id="Sec20"><title>Availability of data and materials</title><p>By contact with corresponding author.</p></sec></sec></body><back><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>GD, CN, and MH designed the study. CN and MH contributed to interpreting the results and writing the manuscript. GD programmed the experiments, supervised data collection, analyzed the data, and drafted the manuscript. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank Roman Allert and Antonia Keller for assistance with patient recruitment and data collection, and Dr. Manuela Kanat and Ines Spenthof for valuable comments on earlier drafts of the manuscript. GD and MH gratefully acknowledge support from the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG; Do1312/2-1; Do1312/2-3; He5310/1-1). The article processing charge was funded by the German Research Foundation (DFG) and the Albert Ludwigs University Freiburg in the funding program Open Access Publishing.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunner</surname><given-names>DL</given-names></name></person-group><article-title>Acute and maintenance treatment of chronic depression</article-title><source>J Clin Psychiatry</source><year>2001</year><volume>62</volume><fpage>10</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">11310814</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>DN</given-names></name></person-group><article-title>Chronic depression: diagnosis and classification</article-title><source>Curr Dir Psychol Sci</source><year>2010</year><volume>19</volume><fpage>96</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1177/0963721410366007</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Brakemeier EL, Engel V, Schramm E, Zobel I, Schmidt T, Hautzinger M, Berger M, Normann C. Feasibility and outcome of cognitive Behavioral Analysis System of Psychotherapy (CBASP) for chronically depressed inpatients: a pilot study. Psychother Psychosom. 2011;80:191&#x02013;4.</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lizardi</surname><given-names>H</given-names></name><name><surname>Klein</surname><given-names>DN</given-names></name><name><surname>Ouimette</surname><given-names>PC</given-names></name><name><surname>Riso</surname><given-names>LP</given-names></name><name><surname>Anderson</surname><given-names>RL</given-names></name><name><surname>Donaldson</surname><given-names>SK</given-names></name></person-group><article-title>Reports of the childhoodhome-environment in early-onset dysthymia and episodic major depression</article-title><source>J Abnorm Psychol</source><year>1995</year><volume>104</volume><fpage>132</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1037/0021-843X.104.1.132</pub-id><pub-id pub-id-type="pmid">7897035</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Kuhnen T, Knappke F, Otto T, Friedrich S, Klein JP, Kahl KG, Huppe M, Sipos V, Schweiger U. Chronic depression: development and evaluation of the luebeck questionnaire for recording preoperational thinking (LQPT). BMC Psychiatry. 2011;11:199.</mixed-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>McCullough</surname><given-names>J</given-names></name></person-group><source>Treatment for chronic depression. Cognitive behavioral analysis system of psychotherapy</source><year>1994</year><publisher-loc>New York</publisher-loc><publisher-name>Guilford Press</publisher-name></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domes</surname><given-names>G</given-names></name><name><surname>Spenthof</surname><given-names>I</given-names></name><name><surname>Radtke</surname><given-names>M</given-names></name><name><surname>Isaksson</surname><given-names>A</given-names></name><name><surname>Normann</surname><given-names>C</given-names></name><name><surname>Heinrichs</surname><given-names>M</given-names></name></person-group><article-title>Autistic traits and empathy in chronic vs. episodic depression</article-title><source>J Affect Disord</source><year>2016</year><volume>195</volume><fpage>144</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2016.02.006</pub-id><pub-id pub-id-type="pmid">26895092</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourke</surname><given-names>C</given-names></name><name><surname>Douglas</surname><given-names>K</given-names></name><name><surname>Porter</surname><given-names>R</given-names></name></person-group><article-title>Processing of facial emotion expression in major depression: a review</article-title><source>Aust N Z J Psychiatry</source><year>2010</year><volume>44</volume><fpage>681</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.3109/00048674.2010.496359</pub-id><pub-id pub-id-type="pmid">20636189</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peckham</surname><given-names>AD</given-names></name><name><surname>McHugh</surname><given-names>RK</given-names></name><name><surname>Otto</surname><given-names>MW</given-names></name></person-group><article-title>A meta-analysis of the magnitude of biased attention in depression</article-title><source>Depress Anxiety</source><year>2010</year><volume>27</volume><fpage>1135</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1002/da.20755</pub-id><pub-id pub-id-type="pmid">21049527</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>CH</given-names></name><name><surname>Hansen</surname><given-names>RD</given-names></name></person-group><article-title>Finding the face in the crowd: an anger superiority effect</article-title><source>J Pers Soc Psychol</source><year>1988</year><volume>54</volume><fpage>917</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1037/0022-3514.54.6.917</pub-id><pub-id pub-id-type="pmid">3397866</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maratos</surname><given-names>FA</given-names></name><name><surname>Mogg</surname><given-names>K</given-names></name><name><surname>Bradley</surname><given-names>BP</given-names></name></person-group><article-title>Identification of angry faces in the attentional blink</article-title><source>Cognit Emot</source><year>2008</year><volume>22</volume><fpage>1340</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1080/02699930701774218</pub-id><pub-id pub-id-type="pmid">19360116</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacLeod</surname><given-names>C</given-names></name><name><surname>Mathews</surname><given-names>A</given-names></name><name><surname>Tata</surname><given-names>P</given-names></name></person-group><article-title>Attentional bias in emotional disorders</article-title><source>J Abnorm Psychol</source><year>1986</year><volume>95</volume><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1037/0021-843X.95.1.15</pub-id><pub-id pub-id-type="pmid">3700842</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bar-Haim</surname><given-names>Y</given-names></name><name><surname>Lamy</surname><given-names>D</given-names></name><name><surname>Pergamin</surname><given-names>L</given-names></name><name><surname>Bakermans-Kranenburg</surname><given-names>MJ</given-names></name><name><surname>van IJzendoorn</surname><given-names>MH</given-names></name></person-group><article-title>Threat-related attentional bias in anxious and nonanxious individuals: a meta-analytic study</article-title><source>Psychol Bull</source><year>2007</year><volume>133</volume><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1037/0033-2909.133.1.1</pub-id><pub-id pub-id-type="pmid">17201568</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradley</surname><given-names>BP</given-names></name><name><surname>Mogg</surname><given-names>K</given-names></name><name><surname>Falla</surname><given-names>SJ</given-names></name><name><surname>Hamilton</surname><given-names>LR</given-names></name></person-group><article-title>Attentional bias for threatening facial expressions in anxiety: manipulation of stimulus duration</article-title><source>Cognit Emot</source><year>1998</year><volume>12</volume><fpage>737</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1080/026999398379411</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Bradley BP, Mogg K, Millar N, BonhamCarter C, Fergusson E, Jenkins J, Parr M. Attentional biases for emotional faces. Cognit Emot. 1997;11:25&#x02013;42.</mixed-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joormann</surname><given-names>J</given-names></name><name><surname>Gotlib</surname><given-names>IH</given-names></name></person-group><article-title>Selective attention to emotional faces following recovery from depression</article-title><source>J Abnorm Psychol</source><year>2007</year><volume>116</volume><fpage>80</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1037/0021-843X.116.1.80</pub-id><pub-id pub-id-type="pmid">17324018</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotlib</surname><given-names>IH</given-names></name><name><surname>Krasnoperova</surname><given-names>E</given-names></name><name><surname>Yue</surname><given-names>DN</given-names></name><name><surname>Joormann</surname><given-names>J</given-names></name></person-group><article-title>Attentional biases for negative interpersonal stimuli in clinical depression</article-title><source>J Abnorm Psychol</source><year>2004</year><volume>113</volume><fpage>121</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">14992665</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leyman</surname><given-names>L</given-names></name><name><surname>De Raedt</surname><given-names>R</given-names></name><name><surname>Schacht</surname><given-names>R</given-names></name><name><surname>Koster</surname><given-names>EH</given-names></name></person-group><article-title>Attentional biases for angry faces in unipolar depression</article-title><source>Psychol Med</source><year>2007</year><volume>37</volume><fpage>393</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1017/S003329170600910X</pub-id><pub-id pub-id-type="pmid">17076914</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mogg</surname><given-names>K</given-names></name><name><surname>Millar</surname><given-names>N</given-names></name><name><surname>Bradley</surname><given-names>BP</given-names></name></person-group><article-title>Biases in eye movements to threatening facial expressions in generalized anxiety disorder and depressive disorder</article-title><source>J Abnorm Psychol</source><year>2000</year><volume>109</volume><fpage>695</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1037/0021-843X.109.4.695</pub-id><pub-id pub-id-type="pmid">11195993</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>E</given-names></name><name><surname>Russo</surname><given-names>R</given-names></name><name><surname>Bowles</surname><given-names>R</given-names></name><name><surname>Dutton</surname><given-names>K</given-names></name></person-group><article-title>Do threatening stimuli draw or hold visual attention in subclinical anxiety?</article-title><source>J Exp Psychol Gen</source><year>2001</year><volume>130</volume><fpage>681</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1037/0096-3445.130.4.681</pub-id><pub-id pub-id-type="pmid">11757875</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koster</surname><given-names>EH</given-names></name><name><surname>Crombez</surname><given-names>G</given-names></name><name><surname>Verschuere</surname><given-names>B</given-names></name><name><surname>De Houwer</surname><given-names>J</given-names></name></person-group><article-title>Selective attention to threat in the dot probe paradigm: differentiating vigilance and difficulty to disengage</article-title><source>Behav Res Ther</source><year>2004</year><volume>42</volume><fpage>1183</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.brat.2003.08.001</pub-id><pub-id pub-id-type="pmid">15350857</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinrichs</surname><given-names>M</given-names></name><name><surname>von Dawans</surname><given-names>B</given-names></name><name><surname>Domes</surname><given-names>G</given-names></name></person-group><article-title>Oxytocin, vasopressin, and human social behavior</article-title><source>Front Neuroendocrinol</source><year>2009</year><volume>30</volume><fpage>548</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.yfrne.2009.05.005</pub-id><pub-id pub-id-type="pmid">19505497</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer-Lindenberg</surname><given-names>A</given-names></name><name><surname>Domes</surname><given-names>G</given-names></name><name><surname>Kirsch</surname><given-names>P</given-names></name><name><surname>Heinrichs</surname><given-names>M</given-names></name></person-group><article-title>Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine</article-title><source>Nat Rev Neurosci</source><year>2011</year><volume>12</volume><fpage>524</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1038/nrn3044</pub-id><pub-id pub-id-type="pmid">21852800</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahrestani</surname><given-names>S</given-names></name><name><surname>Kemp</surname><given-names>AH</given-names></name><name><surname>Guastella</surname><given-names>AJ</given-names></name></person-group><article-title>The impact of a single administration of intranasal oxytocin on the recognition of basic emotions in humans: a meta-analysis</article-title><source>Neuropsychopharmacology</source><year>2013</year><volume>38</volume><fpage>1929</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1038/npp.2013.86</pub-id><pub-id pub-id-type="pmid">23575742</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marsh</surname><given-names>AA</given-names></name><name><surname>Yu</surname><given-names>HH</given-names></name><name><surname>Pine</surname><given-names>DS</given-names></name><name><surname>Blair</surname><given-names>RJ</given-names></name></person-group><article-title>Oxytocin improves specific recognition of positive facial expressions</article-title><source>Psychopharmacology (Berl)</source><year>2010</year><volume>209</volume><fpage>225</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1007/s00213-010-1780-4</pub-id><pub-id pub-id-type="pmid">20186397</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulze</surname><given-names>L</given-names></name><name><surname>Lischke</surname><given-names>A</given-names></name><name><surname>Greif</surname><given-names>J</given-names></name><name><surname>Herpertz</surname><given-names>SC</given-names></name><name><surname>Heinrichs</surname><given-names>M</given-names></name><name><surname>Domes</surname><given-names>G</given-names></name></person-group><article-title>Oxytocin increases recognition of masked emotional faces</article-title><source>Psychoneuroendocrinology</source><year>2011</year><volume>36</volume><fpage>1378</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2011.03.011</pub-id><pub-id pub-id-type="pmid">21477929</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lischke</surname><given-names>A</given-names></name><name><surname>Berger</surname><given-names>C</given-names></name><name><surname>Prehn</surname><given-names>K</given-names></name><name><surname>Heinrichs</surname><given-names>M</given-names></name><name><surname>Herpertz</surname><given-names>SC</given-names></name><name><surname>Domes</surname><given-names>G</given-names></name></person-group><article-title>Intranasal oxytocin enhances emotion recognition from dynamic facial expressions but leaves eye-gaze unaffected</article-title><source>Psychoneuroendocrinology</source><year>2012</year><volume>37</volume><fpage>475</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2011.07.015</pub-id><pub-id pub-id-type="pmid">21862223</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domes</surname><given-names>G</given-names></name><name><surname>Heinrichs</surname><given-names>M</given-names></name><name><surname>Michel</surname><given-names>A</given-names></name><name><surname>Berger</surname><given-names>C</given-names></name><name><surname>Herpertz</surname><given-names>SC</given-names></name></person-group><article-title>Oxytocin improves &#x0201c;mind-reading&#x0201d; in humans</article-title><source>Biol Psychiatry</source><year>2007</year><volume>61</volume><fpage>731</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2006.07.015</pub-id><pub-id pub-id-type="pmid">17137561</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domes</surname><given-names>G</given-names></name><name><surname>Kumbier</surname><given-names>E</given-names></name><name><surname>Heinrichs</surname><given-names>M</given-names></name><name><surname>Herpertz</surname><given-names>SC</given-names></name></person-group><article-title>Oxytocin promotes facial emotion recognition and amygdala reactivity in adults with Asperger syndrome</article-title><source>Neuropsychopharmacology</source><year>2014</year><volume>39</volume><fpage>698</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1038/npp.2013.254</pub-id><pub-id pub-id-type="pmid">24067301</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ, Lambert TJ, Hickie IB. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry. 2010;67:692&#x02013;4.</mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Pedersen CA, Gibson CM, Rau SW, Salimi K, Smedley KL, Casey RL, Leserman J, Jarskog LF, Penn DL. Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophr Res. 2011;132:50&#x02013;3.</mixed-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Averbeck</surname><given-names>BB</given-names></name><name><surname>Bobin</surname><given-names>T</given-names></name><name><surname>Evans</surname><given-names>S</given-names></name><name><surname>Shergill</surname><given-names>SS</given-names></name></person-group><article-title>Emotion recognition and oxytocin in patients with schizophrenia</article-title><source>Psychol Med.</source><year>2012</year><volume>42</volume><fpage>259</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1017/S0033291711001413</pub-id><pub-id pub-id-type="pmid">21835090</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domes</surname><given-names>G</given-names></name><name><surname>Sibold</surname><given-names>M</given-names></name><name><surname>Schulze</surname><given-names>L</given-names></name><name><surname>Lischke</surname><given-names>A</given-names></name><name><surname>Herpertz</surname><given-names>SC</given-names></name><name><surname>Heinrichs</surname><given-names>M</given-names></name></person-group><article-title>Intranasal oxytocin increases covert attention to positive social cues</article-title><source>Psychol Med</source><year>2013</year><volume>43</volume><fpage>1747</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1017/S0033291712002565</pub-id><pub-id pub-id-type="pmid">23146328</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellenbogen</surname><given-names>MA</given-names></name><name><surname>Linnen</surname><given-names>AM</given-names></name><name><surname>Grumet</surname><given-names>R</given-names></name><name><surname>Cardoso</surname><given-names>C</given-names></name><name><surname>Joober</surname><given-names>R</given-names></name></person-group><article-title>The acute effects of intranasal oxytocin on automatic and effortful attentional shifting to emotional faces</article-title><source>Psychophysiology</source><year>2012</year><volume>49</volume><fpage>128</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1111/j.1469-8986.2011.01278.x</pub-id><pub-id pub-id-type="pmid">22092248</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domes</surname><given-names>G</given-names></name><name><surname>Steiner</surname><given-names>A</given-names></name><name><surname>Porges</surname><given-names>SW</given-names></name><name><surname>Heinrichs</surname><given-names>M</given-names></name></person-group><article-title>Oxytocin differentially modulates eye gaze to naturalistic social signals of happiness and anger</article-title><source>Psychoneuroendocrinology</source><year>2013</year><volume>38</volume><fpage>1198</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2012.10.002</pub-id><pub-id pub-id-type="pmid">23117026</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gamer</surname><given-names>M</given-names></name><name><surname>Zurowski</surname><given-names>B</given-names></name><name><surname>Buchel</surname><given-names>C</given-names></name></person-group><article-title>Different amygdala subregions mediate valence-related and attentional effects of oxytocin in humans</article-title><source>Proc Natl Acad Sci U S A</source><year>2010</year><volume>107</volume><fpage>9400</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1073/pnas.1000985107</pub-id><pub-id pub-id-type="pmid">20421469</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guastella</surname><given-names>AJ</given-names></name><name><surname>Mitchell</surname><given-names>PB</given-names></name><name><surname>Dadds</surname><given-names>MR</given-names></name></person-group><article-title>Oxytocin increases gaze to the eye region of human faces</article-title><source>Biol Psychiatry</source><year>2008</year><volume>63</volume><fpage>3</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2007.06.026</pub-id><pub-id pub-id-type="pmid">17888410</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">MacDonald K, MacDonald TM, Brune M, Lamb K, Wilson MP, Golshan S, Feifel D. Oxytocin and psychotherapy: a pilot study of its physiological, behavioral and subjective effects in males with depression. Psychoneuroendocrinology. 2013;38:2831&#x02013;43.</mixed-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scantamburlo</surname><given-names>G</given-names></name><name><surname>Ansseau</surname><given-names>M</given-names></name><name><surname>Geenen</surname><given-names>V</given-names></name><name><surname>Legros</surname><given-names>JJ</given-names></name></person-group><article-title>Intranasal oxytocin as an adjunct to escitalopram in major depression</article-title><source>J Neuropsychiatry Clin Neurosci</source><year>2011</year><volume>23</volume><pub-id pub-id-type="doi">10.1176/jnp.23.2.jnpe5</pub-id><pub-id pub-id-type="pmid">21677229</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="other">Woody ML, Owens M, Burkhouse KL, Gibb BE. Selective attention toward angry faces and risk for major depressive disorder in women: converging evidence from retrospective and prospective analyses. Clin Psychol Sci. 2015; Epub ahead of print. doi: 10.1177/2167702615581580.</mixed-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>AT</given-names></name><name><surname>Hautzinger</surname><given-names>M</given-names></name><name><surname>Bailer</surname><given-names>M</given-names></name><name><surname>Worall</surname><given-names>H</given-names></name><name><surname>Keller</surname><given-names>F</given-names></name></person-group><source>BDI Beck-Depressions-Inventar [BDI Beck Depression Inventory]</source><year>1995</year><publisher-loc>G&#x000f6;ttingen</publisher-loc><publisher-name>Hogrefe</publisher-name></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Laux</surname><given-names>L</given-names></name><name><surname>Glanzmann</surname><given-names>P</given-names></name><name><surname>Schaffner</surname><given-names>P</given-names></name><name><surname>Spielberger</surname><given-names>CD</given-names></name></person-group><source>STAI Das State-Trait-Angstinventar [State-Trait Anxiety Inventory]</source><year>1981</year><publisher-loc>G&#x000f6;ttingen</publisher-loc><publisher-name>Hogrefe</publisher-name></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Steyer</surname><given-names>R</given-names></name><name><surname>Schwenkmezger</surname><given-names>P</given-names></name><name><surname>Notz</surname><given-names>P</given-names></name><name><surname>Eid</surname><given-names>M</given-names></name></person-group><source>Der Mehrdimensionale Befindlichkeitsfragebogen MDBF [Multidimensional mood questionnaire]</source><year>1997</year><publisher-loc>G&#x000f6;ttingen</publisher-loc><publisher-name>Hogrefe</publisher-name></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lundqvist</surname><given-names>D</given-names></name><name><surname>Flykt</surname><given-names>A</given-names></name><name><surname>Ohman</surname><given-names>A</given-names></name></person-group><source>The Karolinska Directed Emotional Faces (KDEF)</source><year>1998</year><publisher-loc>Stockholm</publisher-loc><publisher-name>Department of Clinical Neurosciences, Psychology Section</publisher-name></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotlib</surname><given-names>IH</given-names></name><name><surname>Kasch</surname><given-names>KL</given-names></name><name><surname>Traill</surname><given-names>S</given-names></name><name><surname>Joormann</surname><given-names>J</given-names></name><name><surname>Arnow</surname><given-names>BA</given-names></name><name><surname>Johnson</surname><given-names>SL</given-names></name></person-group><article-title>Coherence and specificity of information-processing biases in depression and social phobia</article-title><source>J Abnorm Psychol</source><year>2004</year><volume>113</volume><fpage>386</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1037/0021-843X.113.3.386</pub-id><pub-id pub-id-type="pmid">15311984</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domes</surname><given-names>G</given-names></name><name><surname>Schulze</surname><given-names>L</given-names></name><name><surname>Herpertz</surname><given-names>SC</given-names></name></person-group><article-title>Emotion recognition in borderline personality disorder-a review of the literature</article-title><source>J Pers Disord</source><year>2009</year><volume>23</volume><fpage>6</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1521/pedi.2009.23.1.6</pub-id><pub-id pub-id-type="pmid">19267658</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenske</surname><given-names>S</given-names></name><name><surname>Lis</surname><given-names>S</given-names></name><name><surname>Liebke</surname><given-names>L</given-names></name><name><surname>Niedtfeld</surname><given-names>I</given-names></name><name><surname>Kirsch</surname><given-names>P</given-names></name><name><surname>Mier</surname><given-names>D</given-names></name></person-group><article-title>Emotion recognition in borderline personality disorder: effects of emotional information on negative bias</article-title><source>Borderline Personal Disord Emot Dysregul</source><year>2015</year><volume>2</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.1186/s40479-015-0031-z</pub-id><pub-id pub-id-type="pmid">26401312</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanat</surname><given-names>M</given-names></name><name><surname>Heinrichs</surname><given-names>M</given-names></name><name><surname>Domes</surname><given-names>G</given-names></name></person-group><article-title>Oxytocin and the social brain: neural mechanisms and perspectives in human research</article-title><source>Brain Res.</source><year>2014</year><volume>1580</volume><fpage>160</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2013.11.003</pub-id><pub-id pub-id-type="pmid">24216134</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinrichs</surname><given-names>M</given-names></name><name><surname>Domes</surname><given-names>G</given-names></name></person-group><article-title>Neuropeptides and social behaviour: effects of oxytocin and vasopressin in humans</article-title><source>Prog Brain Res</source><year>2008</year><volume>170</volume><fpage>337</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/S0079-6123(08)00428-7</pub-id><pub-id pub-id-type="pmid">18655894</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domes</surname><given-names>G</given-names></name><name><surname>Heinrichs</surname><given-names>M</given-names></name><name><surname>Kumbier</surname><given-names>E</given-names></name><name><surname>Grossmann</surname><given-names>A</given-names></name><name><surname>Hauenstein</surname><given-names>K</given-names></name><name><surname>Herpertz</surname><given-names>SC</given-names></name></person-group><article-title>Effects of intranasal oxytocin on the neural basis of face processing in autism spectrum disorder</article-title><source>Biol Psychiatry</source><year>2013</year><volume>74</volume><fpage>164</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2013.02.007</pub-id><pub-id pub-id-type="pmid">23510581</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andari</surname><given-names>E</given-names></name><name><surname>Duhamel</surname><given-names>JR</given-names></name><name><surname>Zalla</surname><given-names>T</given-names></name><name><surname>Herbrecht</surname><given-names>E</given-names></name><name><surname>Leboyer</surname><given-names>M</given-names></name><name><surname>Sirigu</surname><given-names>A</given-names></name></person-group><article-title>Promoting social behavior with oxytocin in high-functioning autism spectrum disorders</article-title><source>Proc Natl Acad Sci U S A</source><year>2010</year><volume>107</volume><fpage>4389</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1073/pnas.0910249107</pub-id><pub-id pub-id-type="pmid">20160081</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartz</surname><given-names>JA</given-names></name><name><surname>Hollander</surname><given-names>E</given-names></name></person-group><article-title>Oxytocin and experimental therapeutics in autism spectrum disorders</article-title><source>Prog Brain Res</source><year>2008</year><volume>170</volume><fpage>451</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/S0079-6123(08)00435-4</pub-id><pub-id pub-id-type="pmid">18655901</pub-id></element-citation></ref></ref-list></back></article>